PubMed

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM; PEGASYS International Study Group.

Ann Intern Med. 2004 Mar 2;140(5):346-55.PMID: 14996676 [PubMed - indexed for MEDLINE]Related articlesFree article

Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial.

Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandão-Mello CE, Reddy KR, Craxi A, Martin AO, Teuber G, Messinger D, Thommes JA, Tietz A.

Ann Intern Med. 2009 Apr 21;150(8):528-40.PMID: 19380853 [PubMed - indexed for MEDLINE]Related articlesFree article

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Solá R, Shafran SD, Barange K, Lin A, Soman A, Zeuzem S; ACCELERATE Investigators.

N Engl J Med. 2007 Jul 12;357(2):124-34.PMID: 17625124 [PubMed - indexed for MEDLINE]Related articlesFree article

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS; IDEAL Study Team.

N Engl J Med. 2009 Aug 6;361(6):580-93. Epub 2009 Jul 22. Erratum in: N Engl J Med. 2009 Sep 3;361(10):1027. PMID: 19625712 [PubMed - indexed for MEDLINE]Related articles

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, Bergk A, Bernsmeier C, Häussinger D, Herrmann E, Zeuzem S.

Gastroenterology. 2005 Aug;129(2):522-7.PMID: 16083709 [PubMed - indexed for MEDLINE]Related articles

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.

Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Peters MG, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C; AIDS Clinical Trials Group A5071 Study Team.

N Engl J Med. 2004 Jul 29;351(5):451-9.PMID: 15282352 [PubMed - indexed for MEDLINE]Related articlesFree article

Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.

Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB.

Gastroenterology. 2009 Mar;136(3):856-62. Epub 2008 Nov 19.PMID: 19135998 [PubMed - indexed for MEDLINE]Related articles

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.

Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourlière M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S; PROVE2 Study Team.

N Engl J Med. 2009 Apr 30;360(18):1839-50.PMID: 19403903 [PubMed - indexed for MEDLINE]Related articlesFree article

[Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea]

Lee H, Choi MS, Paik SW, Kim JH, Kim DY, Lee JH, Koh KC, Yoo BC, Rhee JC, Song SM.

Korean J Hepatol. 2006 Mar;12(1):31-40. Korean. PMID: 16565604 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.

Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J, Bourlière M, Renou C, Tran A, Melin P, Hézode C, Chevalier M, Bouvier-Alias M, Chevaliez S, Montestruc F, Lonjon-Domanec I, Pawlotsky JM.

Gastroenterology. 2006 Oct;131(4):1040-8. Epub 2006 Jul 24.PMID: 17030174 [PubMed - indexed for MEDLINE]Related articles

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H Jr, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT; APRICOT Study Group.

N Engl J Med. 2004 Jul 29;351(5):438-50.PMID: 15282351 [PubMed - indexed for MEDLINE]Related articlesFree article

Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy.

Parise E, Cheinquer H, Crespo D, Meirelles A, Martinelli A, Sette H, Gallizi J, Silva R, Lacet C, Correa E, Cotrim H, Fonseca J, Paraná R, Spinelli V, Amorim W, Tatsch F, Pessoa M; Brazilian Pegasys Cooperative Study Group.

Braz J Infect Dis. 2006 Feb;10(1):11-6. Epub 2006 Jun 2.PMID: 16767309 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C.

Malone DC, Tran TT, Poordad FF.

J Manag Care Pharm. 2005 Oct;11(8):687-94.PMID: 16194133 [PubMed - indexed for MEDLINE]Related articlesFree article

A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C.

Yu ML, Dai CY, Huang JF, Hou NJ, Lee LP, Hsieh MY, Chiu CF, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL.

Gut. 2007 Apr;56(4):553-9. Epub 2006 Sep 6.PMID: 16956917 [PubMed - indexed for MEDLINE]Related articles

Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial.

Mangia A, Minerva N, Bacca D, Cozzolongo R, Ricci GL, Carretta V, Vinelli F, Scotto G, Montalto G, Romano M, Cristofaro G, Mottola L, Spirito F, Andriulli A.

Hepatology. 2008 Jan;47(1):43-50.PMID: 18069698 [PubMed - indexed for MEDLINE]Related articles

International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C.

Zeuzem S, Pawlotsky JM, Lukasiewicz E, von Wagner M, Goulis I, Lurie Y, Gianfranco E, Vrolijk JM, Esteban JI, Hezode C, Lagging M, Negro F, Soulier A, Verheij-Hart E, Hansen B, Tal R, Ferrari C, Schalm SW, Neumann AU; DITTO-HCV Study Group.

J Hepatol. 2005 Aug;43(2):250-7.PMID: 16082736 [PubMed - indexed for MEDLINE]Related articles

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.

Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, Buggisch P, Goeser T, Rasenack J, Pape GR, Schmidt WE, Kallinowski B, Klinker H, Spengler U, Martus P, Alshuth U, Zeuzem S.

Gastroenterology. 2006 Apr;130(4):1086-97.PMID: 16618403 [PubMed - indexed for MEDLINE]Related articles

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J.

N Engl J Med. 2002 Sep 26;347(13):975-82.PMID: 12324553 [PubMed - indexed for MEDLINE]Related articlesFree article

Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response.

Howell CD, Jeffers LS, Cassidy W, Reddy KR, Hu S, Lee JS.

J Viral Hepat. 2006 Jun;13(6):371-6.PMID: 16842439 [PubMed - indexed for MEDLINE]Related articles

Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.

Gallegos-Orozco JF, Fuentes AP, Olivera-Martinez MA, Gutiérrez-Reyes G, Cortina D, Oregel JA, Pérez-Pruna C, Sixtos MS, Cruz-Castellanos S, Soto-Ramírez LE, Rodríguez-Díaz R, Fuentes-Romero L, Gutiérrez-Ruiz MC, Kershenobich D.

Rev Invest Clin. 2003 Mar-Apr;55(2):138-42.PMID: 12827916 [PubMed - indexed for MEDLINE]Related articles